Complete enrollment in the interim analysis cohort of the AMPLITUDE trial of inaxaplin
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Feb 2025
- Due
- 31 Dec 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Vertex expects to complete enrollment in the interim analysis cohort in 2025”
What we found
Evidence strength A What the grades mean
Later filings state Vertex completed enrollment in the AMPLITUDE interim analysis cohort in September 2025, before the 2025 deadline.
-
A Vertex Pharmaceuticals 8-K filed 2026-02-12
“In September, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in people with primary AMKD” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 10-K filed 2026-02-13
“We completed enrollment of the interim analysis cohort of AMPLITUDE in 2025” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 8-K filed 2026-05-04
“In the second half of 2025, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin” ✓ confirmed on the page
Market reaction: the shares moved +4.8% against the S&P 500 over the three sessions around the disclosure (11 Feb 2026 to 17 Feb 2026). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Enrollment of AMPLITUDE interim analysis cohort
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-VRTX-006548 · Corrections policy